Abstracts by key term: Statutory health insurance
In an increasingly volatile and fast-moving time, brands are becoming more and more important for consumers - also in their role as health insured people. However, if the brand image created by the company does not match the actual brand identity, dissonances occur with counterproductive effects. An aspect that is becoming more important than ever for statutory health insurance companies (GKVn), among other things due to the resulting market confusion and product diversity.
02.10.2012
For years, numerous national and international publications have confirmed that in Germany, by international comparison, too few medically necessary operations are performed on an outpatient basis (Brökelmann 2007: 5; Toftgaard/Parmentier 2006: 42-48). Although it is known that some of these deviations can also be explained by different organizational and financial factors in the respective countries, the deviations in some operations are still too clear for these explanations to be used as the sole justification for the differences (Busse/Wörtz 2009: 52 – 54; Oberender & Partner 2010: 26 – 28).
24.02.2012
Discount contracts have played a prominent role in the pharmaceutical supply of statutory health insurance (GKV). This competitive field has undergone dramatic change in many respects. Not only contract design, implementation, but also legal assessment and public perception have changed. Implementation problems from the beginning have largely been resolved. The savings from the contracts are essential for the GKV - every statutory health insurance company has reported numerous contracts. The article provides an overview of the experiences of the German BKK.
01.06.2010
The aim of the present analysis is to compare treatment costs between insulin-glargine and NPH-insulin-based therapies in patients with diabetes mellitus. Using a representative sample of health insurance data, simultaneous co-medication in the indication groups bolus insulin, oral antidiabetics, test strips and lancets/needles over three calendar years was determined for a total of six payers. During the analysis period (2006 - 2008), the aggregated absolute annual treatment costs per diabetes patient for insulin glargine-based therapies tended to be slightly below the costs of the respective NPH comparison groups. The analysis of the individual costs shows that the higher procurement costs for insulin glargine are overcompensated by savings in bolus insulin and test strip consumption. The present database analysis confirms the results of previously published health care research studies, according to which, from the perspective of statutory health insurance (GKV), there is a cost-neutrality between insulin glargine and NPH insulin-based treatment regimens under real care conditions.
01.12.2009
It is currently becoming apparent that the discount agreements are reinforcing a development that leads to market results that do not do justice to the relative or absolute value of the medicines and thus lead to allocative inefficiencies. Against this background, a proposal for a central approach to controlling the generic drug market, based on a cost-benefit assessment, was developed. The core of the model is that the reimbursement prices in the statutory health insurance are set in such a way that they reflect the benefit ratio of the drugs to each other. In this way, the approach induces a needs-oriented and efficient distribution of scarce resources in drug supply. The approach also offers a pragmatic multi-step scenario with budget neutrality in the introduction phase of the model.